Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KYNU | Q16719 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336395 | 0.91 | CTSS (0.46) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL2715828 | 0.80 | CTSS (0.52) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1508989 | 0.79 | CTSB (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1508777 | 0.79 | CTSB (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL6304830 | 0.78 | CTSL (0.48) | CTSSCTSLCTSBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1189554 | 0.78 | CTSS (0.57) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL7918135 | 0.77 | CTSB (0.45) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL7954342 | 0.77 | CTSB (0.45) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL13383514 | 0.77 | NPSR1 (0.45) | CTSSNPC1RAB9ACTSKNPSR1 | |
| Hydrochloric Acid SCHEMBL29158039 | 0.76 | CTSS (0.56) | CTSSCTSLCTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010082612-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2010044401-A1 | MORPHOLINOPURINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009151069-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIRO[2.5]OCTANE RING STRUCTURE | 第一三共株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | MDM2, TP53, TP53BP1 | CTSS 3085/4885CTSL 2446/4885CTSB 2870/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | CTSS 4820/4885CTSL 4767/4885CTSB 4621/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | CTSS 4820/4885CTSL 4767/4885CTSB 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.